Citations (99)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (12)
Yuki Yamaguchi, Natsumi Wakaizumi, Mine Irisa, Takahiro Maruno, Mari Shimada, Koya Shintani, Haruka Nishiumi, Rina Yogo, Saeko Yanaka, Daisuke Higo, Tetsuo Torisu, Koichi Kato & Susumu Uchiyama. (2022) The Fab portion of immunoglobulin G has sites in the CL domain that interact with Fc gamma receptor IIIa. mAbs 14:1.
Read now
Read now
Rebecca P Chen, Kenta Shinoda, Pragya Rampuria, Fang Jin, Tin Bartholomew, Chunxia Zhao, Fan Yang & Javier Chaparro-Riggers. (2022) Bispecific antibodies for immune cell retargeting against cancer. Expert Opinion on Biological Therapy 22:8, pages 965-982.
Read now
Read now
Stephanie Sasse, Paul Jan Bröckelmann, Jesko Momotow, Annette Plütschow, Andreas Hüttmann, Nadezda Basara, Christian Koenecke, Sonja Martin, Martin Bentz, Christina Grosse-Thie, Sven Thorspecken, Maike de Wit, Carsten Kobe, Markus Dietlein, Bastian von Tresckow, Michael Fuchs, Peter Borchmann & Andreas Engert. (2022) AFM13 in patients with relapsed or refractory classical Hodgkin lymphoma: final results of an open-label, randomized, multicenter phase II trial. Leukemia & Lymphoma 63:8, pages 1871-1878.
Read now
Read now
Susanne Wingert, Uwe Reusch, Stefan Knackmuss, Michael Kluge, Michael Damrat, Jens Pahl, Ute Schniegler-Mattox, Thomas Mueller, Ivica Fucek, Kristina Ellwanger, Michael Tesar, Torsten Haneke, Joachim Koch, Martin Treder, Wolfgang Fischer & Erich Rajkovic. (2021) Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors. mAbs 13:1.
Read now
Read now
Yining Zhao, Yumei Li, Xiaoqiong Wu, Li Li, Jiayu Liu, Yanlan Wang, Yue Liu, Qing Li & Zhong Wang. (2020) Identification of anti-CD16a single domain antibodies and their application in bispecific antibodies. Cancer Biology & Therapy 21:1, pages 72-80.
Read now
Read now
Kristina Ellwanger, Uwe Reusch, Ivica Fucek, Susanne Wingert, Thorsten Ross, Thomas Müller, Ute Schniegler-Mattox, Torsten Haneke, Erich Rajkovic, Joachim Koch, Martin Treder & Michael Tesar. (2019) Redirected optimized cell killing (ROCK®): A highly versatile multispecific fit-for-purpose antibody platform for engaging innate immunity. mAbs 11:5, pages 899-918.
Read now
Read now
Roland B. Walter. (2018) Investigational CD33-targeted therapeutics for acute myeloid leukemia. Expert Opinion on Investigational Drugs 27:4, pages 339-348.
Read now
Read now
Ulrich Brinkmann & Roland E. Kontermann. (2017) The making of bispecific antibodies. mAbs 9:2, pages 182-212.
Read now
Read now
Oksana Tyshchuk, Hans Rainer Völger, Claudia Ferrara, Patrick Bulau, Hans Koll & Michael Mølhøj. (2017) Detection of a phosphorylated glycine-serine linker in an IgG-based fusion protein. mAbs 9:1, pages 94-103.
Read now
Read now
Siqi Chen, Jing Li, Qing Li & Zhong Wang. (2016) Bispecific antibodies in cancer immunotherapy. Human Vaccines & Immunotherapeutics 12:10, pages 2491-2500.
Read now
Read now
Archana Thakur & Lawrence G. Lum. (2016) “NextGen” Biologics: Bispecific Antibodies and Emerging Clinical Results. Expert Opinion on Biological Therapy 16:5, pages 675-688.
Read now
Read now
Uwe Reusch, Johannes Duell, Kristina Ellwanger, Carmen Herbrecht, Stefan HJ Knackmuss, Ivica Fucek, Markus Eser, Fionnuala McAleese, Vera Molkenthin, Fabrice Le Gall, Max Topp, Melvyn Little & Eugene A Zhukovsky. (2015) A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19+ tumor cells. mAbs 7:3, pages 584-604.
Read now
Read now
Articles from other publishers (87)
Mehdi Bakhtiyaridovvombaygi, Somayeh Yazdanparast, Fatemeh Mikanik, Amirhossein Izadpanah, Sahar Parkhideh, Amin Shahbaz ghasabeh, Elham Roshandel, Abbas Hajifathali & Ahmad Gharehbaghian. (2023) Cytokine‐Induced Memory‐Like NK Cells: Emerging strategy for AML immunotherapy. Biomedicine & Pharmacotherapy 168, pages 115718.
Crossref
Crossref
Stephanie L. Fetzko, Leander D. Timothy & Robin Parihar. (2023) NK Cell Therapeutics for Hematologic Malignancies: from Potential to Fruition. Current Hematologic Malignancy Reports 18:6, pages 264-272.
Crossref
Crossref
Kim Anh Giang, Thorstein Boxaspen, Yumei Diao, Johan Nilvebrant, Mizuha Kosugi-Kanaya, Minoru Kanaya, Silje Zandstra Krokeide, Fredrik Lehmann, Stefan Svensson Gelius, Karl-Johan Malmberg & Per-Åke Nygren. (2023) Affibody-based hBCMA x CD16 dual engagers for NK cell-mediated killing of multiple myeloma cells. New Biotechnology 77, pages 139-148.
Crossref
Crossref
Qingxia Liu, Qifeng Song, Cheng Luo, Jian Wei, Yao Xu, Liwen Zhao & Yong Wang. (2023) A novel bispecific antibody as an immunotherapeutic agent in hepatocellular carcinoma. Molecular Immunology 162, pages 125-132.
Crossref
Crossref
Michael P. Randall & Michael A. Spinner. (2023) Optimizing Treatment for Relapsed/Refractory Classic Hodgkin Lymphoma in the Era of Immunotherapy. Cancers 15:18, pages 4509.
Crossref
Crossref
Atsushi Kuwahara, Kazunori Ikebukuro & Ryutaro Asano. (2023) Protein engineering of antibody fragments for pharmaceutical production. Applied Physics Reviews 10:3.
Crossref
Crossref
Lu Tang, Zhongpei Huang, Heng Mei & Yu Hu. (2023) Immunotherapy in hematologic malignancies: achievements, challenges and future prospects. Signal Transduction and Targeted Therapy 8:1.
Crossref
Crossref
Mary L. Faber, Robyn A. A. Oldham, Archana Thakur, Mary Jo Rademacher, Ewa Kubicka, Theresa A. Dlugi, Steven A. Gifford, William M. McKillop, Nathan J. Schloemer, Lawrence G. Lum & Jeffrey A. Medin. (2023) Novel anti-CD30/CD3 bispecific antibodies activate human T cells and mediate potent anti-tumor activity. Frontiers in Immunology 14.
Crossref
Crossref
Sameek Singh, Wenzhi Tian, Zachary C. Severance, Santosh K. Chaudhary, Viktoriya Anokhina, Basudeb Mondal, Rajaiah Pergu, Prashant Singh, Uttam Dhawa, Santanu Singha & Amit Choudhary. (2023) Proximity-inducing modalities: the past, present, and future. Chemical Society Reviews 52:16, pages 5485-5515.
Crossref
Crossref
Minchuan Zhang, Kong-Peng Lam & Shengli Xu. (2023) Natural Killer Cell Engagers (NKCEs): a new frontier in cancer immunotherapy. Frontiers in Immunology 14.
Crossref
Crossref
Yan He, Haili Ma, Cong Wang, Zhilong Ai, Qiao Wu, Hongyan Chen & Daru Lu. (2023) A novel brick for bispecific antibody construction. Proteins: Structure, Function, and Bioinformatics 91:8, pages 1065-1076.
Crossref
Crossref
Selma Z. D’Silva, Meenakshi Singh & Andrea S. Pinto. (2023) NK cell defects: implication in acute myeloid leukemia. Frontiers in Immunology 14.
Crossref
Crossref
Yangyang Li, Siqi Xie, Minhua Chen, Hao Li, Yehai Wang, Yan Fan, Kang An, Yu Wu & Weihua Xiao. (2023) Development of an antibody-ligand fusion protein scFvCD16A-sc4-1BBL in Komagataella phaffii with stimulatory activity for Natural Killer cells. Microbial Cell Factories 22:1.
Crossref
Crossref
Alessia Floerchinger, Jessica E. Klein, Maximiliane S. C. Finkbeiner, Theresa E. Schäfer, Gwendolin Fuchs, Johannes Doerner, Hubert Zirngibl, Maximilian Ackermann, Hans M. Kvasnicka, Kerry A. Chester, Dirk Jäger, Claudia R. Ball, Guy Ungerechts & Christine E. Engeland. (2023) A vector-encoded bispecific killer engager to harness virus-activated NK cells as anti-tumor effectors. Cell Death & Disease 14:2.
Crossref
Crossref
Shahryar Khoshtinat Nikkhoi, Geng Li, Suha Eleya, Ge Yang, Venu Gopal Vandavasi & Arash Hatefi. (2023) Bispecific killer cell engager with high affinity and specificity toward CD16a on NK cells for cancer immunotherapy. Frontiers in Immunology 13.
Crossref
Crossref
Sheena Pinto, Jens Pahl, Arndt Schottelius, Paul J. Carter & Joachim Koch. (2022) Reimagining antibody-dependent cellular cytotoxicity in cancer: the potential of natural killer cell engagers. Trends in Immunology 43:11, pages 932-946.
Crossref
Crossref
Tamara J. Laskowski, Alexander Biederstädt & Katayoun Rezvani. (2022) Natural killer cells in antitumour adoptive cell immunotherapy. Nature Reviews Cancer 22:10, pages 557-575.
Crossref
Crossref
Hao Cai, Satoko Kakiuchi-Kiyota, Robert Hendricks, Shelly Zhong, Luna Liu, Adeyemi O. Adedeji, Pamela Chan, Melissa M. Schutten, Amrita V. Kamath & Meric A. Ovacik. (2022) Nonclinical Pharmacokinetics, Pharmacodynamics, and Translational Model of RO7297089, A Novel Anti-BCMA/CD16A Bispecific Tetravalent Antibody for the Treatment of Multiple Myeloma. The AAPS Journal 24:6.
Crossref
Crossref
Anna Helmin-Basa, Lidia Gackowska, Sara Balcerowska, Marcelina Ornawka, Natalia Naruszewicz & Małgorzata Wiese-Szadkowska. (2022) The application of the natural killer cells, macrophages and dendritic cells in treating various types of cancer. Physical Sciences Reviews 7:8, pages 833-866.
Crossref
Crossref
Xin Chen, Lei Jiang & Xuesong Liu. (2022) Natural killer cells: the next wave in cancer immunotherapy. Frontiers in Immunology 13.
Crossref
Crossref
Ha Gyeong Shin, Ha Rim Yang, Aerin Yoon & Sukmook Lee. (2022) Bispecific Antibody-Based Immune-Cell Engagers and Their Emerging Therapeutic Targets in Cancer Immunotherapy. International Journal of Molecular Sciences 23:10, pages 5686.
Crossref
Crossref
Satoko Kakiuchi-Kiyota, Thorsten Ross, Heidi Ackerly Wallweber, James R. Kiefer, Melissa M. Schutten, Adeyemi O. Adedeji, Hao Cai, Robert Hendricks, Sivan Cohen, Srividya Myneni, Luna Liu, Aaron Fullerton, Nicholas Corr, Lanlan Yu, Denise de Almeida Nagata, Shelly Zhong, Steven R. Leong, Ji Li, Rin Nakamura, Teiko Sumiyoshi, Jinze Li, Ayse Meric Ovacik, Bing Zheng, Mike Dillon, Christoph Spiess, Susanne Wingert, Erich Rajkovic, Kristina Ellwanger, Uwe Reusch & Andrew G. Polson. (2022) A BCMA/CD16A bispecific innate cell engager for the treatment of multiple myeloma. Leukemia 36:4, pages 1006-1014.
Crossref
Crossref
Mubin Tarannum, Rizwan Romee & Roman M. Shapiro. (2022) Innovative Strategies to Improve the Clinical Application of NK Cell-Based Immunotherapy. Frontiers in Immunology 13.
Crossref
Crossref
Yaya Chu, Margaret Lamb, Mitchell S. Cairo & Dean A. Lee. (2022) The Future of Natural Killer Cell Immunotherapy for B Cell Non-Hodgkin Lymphoma (B Cell NHL). Current Treatment Options in Oncology 23:3, pages 381-403.
Crossref
Crossref
Uwe Reusch, Kristina Ellwanger, Ivica Fucek, Thomas Müller, Ute Schniegler-Mattox, Joachim Koch & Michael Tesar. (2022) Cryopreservation of Natural Killer Cells Pre-Complexed with Innate Cell Engagers. Antibodies 11:1, pages 12.
Crossref
Crossref
Shijie Jin, Yanping Sun, Xiao Liang, Xinyu Gu, Jiangtao Ning, Yingchun Xu, Shuqing Chen & Liqiang Pan. (2022) Emerging new therapeutic antibody derivatives for cancer treatment. Signal Transduction and Targeted Therapy 7:1.
Crossref
Crossref
Sami El Khatib & Mohamed Salla. (2022) The mosaic puzzle of the therapeutic monoclonal antibodies and antibody fragments - A modular transition from full-length immunoglobulins to antibody mimetics. Leukemia Research Reports 18, pages 100335.
Crossref
Crossref
Ondřej Vaněk, Barbora Kalousková, Celeste Abreu, Shiva Nejadebrahim & Ondřej Skořepa. 2022. Immunotherapeutics. Immunotherapeutics
91
133
.
Pamela D. Garzone & Yow-Ming C. Wang. 2022. Atkinson's Principles of Clinical Pharmacology. Atkinson's Principles of Clinical Pharmacology
611
651
.
Hans Raskov, Adile Orhan, Ali Salanti, Shruti Gaggar & Ismail Gögenur. (2021) Natural Killer Cells in Cancer and Cancer Immunotherapy. Cancer Letters 520, pages 233-242.
Crossref
Crossref
Emily KangCigall KadochJames L. Rubenstein, Lewis L. Lanier & James A. Wells. (2021) A functional mammalian display screen identifies rare antibodies that stimulate NK cell–mediated cytotoxicity. Proceedings of the National Academy of Sciences 118:31.
Crossref
Crossref
Olivier Demaria, Laurent Gauthier, Guilhaume Debroas & Eric Vivier. (2021) Natural killer cell engagers in cancer immunotherapy: Next generation of immuno‐oncology treatments. European Journal of Immunology 51:8, pages 1934-1942.
Crossref
Crossref
Lucila N. Kerbauy, Nancy D. Marin, Mecit Kaplan, Pinaki P. Banerjee, Melissa M. Berrien-Elliott, Michelle Becker-Hapak, Rafet Basar, Mark Foster, Luciana Garcia Melo, Carly C. Neal, Ethan McClain, May Daher, Ana Karen Nunez Cortes, Sweta Desai, Francesca Wei Inng Lim, Mayela Carolina Mendt, Timothy Schappe, Li Li, Hila Shaim, Mayra Shanley, Emily L. Ensley, Nadima Uprety, Pamela Wong, Enli Liu, Sonny O. Ang, Rong Cai, Vandana Nandivada, Vakul Mohanty, Qi Miao, Yifei Shen, Natalia Baran, Natalie W. Fowlkes, Ken Chen, Luis Muniz-Feliciano, Richard E. Champlin, Yago L. Nieto, Joachim Koch, Martin Treder, Wolfgang Fischer, Oswaldo Keith Okamoto, Elizabeth J. Shpall, Todd A. Fehniger & Katayoun Rezvani. (2021) Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood–Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies. Clinical Cancer Research 27:13, pages 3744-3756.
Crossref
Crossref
Henk van Faassen, Dong-Hyeon Jo, Shannon Ryan, Michael J. Lowden, Shalini Raphael, C. Roger MacKenzie, Seung-Hwan Lee, Greg Hussack & Kevin A. Henry. (2021) Incorporation of a Novel CD16-Specific Single-Domain Antibody into Multispecific Natural Killer Cell Engagers With Potent ADCC. Molecular Pharmaceutics 18:6, pages 2375-2384.
Crossref
Crossref
Ames C. Register, Somayeh S. Tarighat & Ho Young Lee. (2021) Bioassay Development for Bispecific Antibodies—Challenges and Opportunities. International Journal of Molecular Sciences 22:10, pages 5350.
Crossref
Crossref
Jiabing Ma, Yicheng Mo, Menglin Tang, Junjie Shen, Yanan Qi, Wenxu Zhao, Yi Huang, Yanmin Xu & Cheng Qian. (2021) Bispecific Antibodies: From Research to Clinical Application. Frontiers in Immunology 12.
Crossref
Crossref
Barbara Pro & Andrei Shustov. 2021. The Peripheral T‐Cell Lymphomas. The Peripheral T‐Cell Lymphomas
329
341
.
John C. Reneau & Ryan A. Wilcox. (2021) Novel therapies targeting cutaneous T cell lymphomas and their microenvironment. Seminars in Hematology 58:2, pages 103-113.
Crossref
Crossref
Clifford M. Csizmar & Stephen M. Ansell. (2021) Engaging the Innate and Adaptive Antitumor Immune Response in Lymphoma. International Journal of Molecular Sciences 22:7, pages 3302.
Crossref
Crossref
Qing Zhao, Jie Pang, Fushan Yan, Yi Jiang, Dongxu Cui, Juanjuan Liu, Lei Jing, Yuyin Li, Zhenxing Liu, Li Tao, Xiaocui Zhao & Aipo Diao. (2021) Production of a novel bispecific protein ULBP1×CD19-scFv targeting the NKG2D receptor and CD19 to promote the activation of NK cells. Protein Expression and Purification 178, pages 105783.
Crossref
Crossref
Zuoqiao Wu, Mary Nicoll & Robert J. Ingham. (2021) AP-1 family transcription factors: a diverse family of proteins that regulate varied cellular activities in classical hodgkin lymphoma and ALK+ ALCL. Experimental Hematology & Oncology 10:1.
Crossref
Crossref
Seyed Samad Hosseini, Saeed Khalili, Behzad Baradaran, Negar Bidar, Mohammad-Ali Shahbazi, Jafar Mosafer, Mahmoud Hashemzaei, Ahad Mokhtarzadeh & Michael R. Hamblin. (2021) Bispecific monoclonal antibodies for targeted immunotherapy of solid tumors: Recent advances and clinical trials. International Journal of Biological Macromolecules 167, pages 1030-1047.
Crossref
Crossref
Feodora R. Kosasih, Silvia Vivarelli, Massimo Libra & Benjamin Bonavida. 2021. Successes and Challenges of NK Immunotherapy. Successes and Challenges of NK Immunotherapy
459
475
.
Le Li & Ying Wang. (2020) Recent updates for antibody therapy for acute lymphoblastic leukemia. Experimental Hematology & Oncology 9:1.
Crossref
Crossref
Nancy L. BartlettAlex F. HerreraEva Domingo-Domenech, Amitkumar Mehta, Andres Forero-TorresRamon Garcia-Sanz, Philippe ArmandSumana DevataAntonia Rodriguez IzquierdoIzidore S. Lossos, Craig ReederTaimur SherRobert ChenSylvia E. SchwarzLeila Alland, Andras StrasszKim PrierCassandra Choe-Juliak & Stephen M. Ansell. (2020) A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma. Blood 136:21, pages 2401-2409.
Crossref
Crossref
Massimo Giuliani & Alessandro Poggi. (2020) Checkpoint Inhibitors and Engineered Cells: New Weapons for Natural Killer Cell Arsenal Against Hematological Malignancies. Cells 9:7, pages 1578.
Crossref
Crossref
Eva Domingo-Domènech & Anna Sureda. (2020) Treatment of Hodgkin Lymphoma Relapsed after Autologous Stem Cell Transplantation. Journal of Clinical Medicine 9:5, pages 1384.
Crossref
Crossref
Margaux Lejeune, Murat Cem Köse, Elodie Duray, Hermann Einsele, Yves Beguin & Jo Caers. (2020) Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies. Frontiers in Immunology 11.
Crossref
Crossref
Yuanlin Wu, Jing Li, Parham Jabbarzadeh Kaboli, Jing Shen, Xu Wu, Yueshui Zhao, Huijiao Ji, Fukuan Du, Yejiang Zhou, Yongzhou Wang, Hanyu Zhang, Jianhua Yin, Qinglian Wen, Chi Hin Cho, Mingxing Li & Zhangang Xiao. (2020) Natural killer cells as a double-edged sword in cancer immunotherapy: A comprehensive review from cytokine therapy to adoptive cell immunotherapy. Pharmacological Research 155, pages 104691.
Crossref
Crossref
Jing Zhang, Jizu Yi & Pengfei Zhou. (2020) Development of bispecific antibodies in China: overview and prospects. Antibody Therapeutics 3:2, pages 126-145.
Crossref
Crossref
Siwei Nie, Zhuozhi Wang, Maria Moscoso-Castro, Paul D'Souza, Can Lei, Jianqing Xu & Jijie Gu. (2020) Biology drives the discovery of bispecific antibodies as innovative therapeutics. Antibody Therapeutics 3:1, pages 18-62.
Crossref
Crossref
Steffen Dickopf, Guy J. Georges & Ulrich Brinkmann. (2020) Format and geometries matter: Structure-based design defines the functionality of bispecific antibodies. Computational and Structural Biotechnology Journal 18, pages 1221-1227.
Crossref
Crossref
Sylvia Dietrich, Alec W. Gross, Stefan Becker, Björn Hock, Gerhard Stadlmayr, Florian Rüker & Gordana Wozniak-Knopp. (2020) Constant domain-exchanged Fab enables specific light chain pairing in heterodimeric bispecific SEED-antibodies. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics 1868:1, pages 140250.
Crossref
Crossref
Raoufeh Ahamadi-Fesharaki, Abolfazl Fateh, Farzam Vaziri, Ghasem Solgi, Seyed Davar Siadat, Fereidoun Mahboudi & Fatemeh Rahimi-Jamnani. (2019) Single-Chain Variable Fragment-Based Bispecific Antibodies: Hitting Two Targets with One Sophisticated Arrow. Molecular Therapy - Oncolytics 14, pages 38-56.
Crossref
Crossref
Olivier Lucar, R. Keith Reeves & Stephanie Jost. (2019) A Natural Impact: NK Cells at the Intersection of Cancer and HIV Disease. Frontiers in Immunology 10.
Crossref
Crossref
Qiong Wang, Yiqun Chen, Jaeyoung Park, Xiao Liu, Yifeng Hu, Tiexin Wang, Kevin McFarland & Michael J. Betenbaugh. (2019) Design and Production of Bispecific Antibodies. Antibodies 8:3, pages 43.
Crossref
Crossref
Shaheer Khan & Ahmed Sawas. (2019) Antibody-Directed Therapies: Toward a Durable and Tolerable Treatment Platform for CTCL. Frontiers in Oncology 9.
Crossref
Crossref
Shixue Chen, Lingling Li, Fan Zhang, Yu Wang, Yi Hu & Lei Zhao. (2019) Immunoglobulin Gamma-Like Therapeutic Bispecific Antibody Formats for Tumor Therapy. Journal of Immunology Research 2019, pages 1-13.
Crossref
Crossref
Diego Ellerman. (2019) Bispecific T-cell engagers: Towards understanding variables influencing the in vitro potency and tumor selectivity and their modulation to enhance their efficacy and safety. Methods 154, pages 102-117.
Crossref
Crossref
Archana Thakur, Manley Huang & Lawrence G. Lum. (2018) Bispecific antibody based therapeutics: Strengths and challenges. Blood Reviews 32:4, pages 339-347.
Crossref
Crossref
Jens H.W. Pahl, Joachim Koch, Jana-Julia Götz, Annette Arnold, Uwe Reusch, Thorsten Gantke, Erich Rajkovic, Martin Treder & Adelheid Cerwenka. (2018) CD16A Activation of NK Cells Promotes NK Cell Proliferation and Memory-Like Cytotoxicity against Cancer Cells. Cancer Immunology Research 6:5, pages 517-527.
Crossref
Crossref
Anuradha Krishnamurthy & Antonio Jimeno. (2018) Bispecific antibodies for cancer therapy: A review. Pharmacology & Therapeutics 185, pages 122-134.
Crossref
Crossref
Jodi Chiu, Daniel M. Ernst & Armand Keating. (2018) Acquired Natural Killer Cell Dysfunction in the Tumor Microenvironment of Classic Hodgkin Lymphoma. Frontiers in Immunology 9.
Crossref
Crossref
Eva Dahlén, Niina Veitonmäki & Per Norlén. (2018) Bispecific antibodies in cancer immunotherapy. Therapeutic Advances in Vaccines and Immunotherapy 6:1, pages 3-17.
Crossref
Crossref
Asim Azhar, Ejaj Ahmad, Qamar Zia, Mohd. Ahmar Rauf, Mohammad Owais & Ghulam Md Ashraf. (2017) Recent advances in the development of novel protein scaffolds based therapeutics. International Journal of Biological Macromolecules 102, pages 630-641.
Crossref
Crossref
Hongyan Liu, Abhishek Saxena, Sachdev S. Sidhu & Donghui Wu. (2017) Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds. Frontiers in Immunology 8.
Crossref
Crossref
Joachim Koch & Michael Tesar. (2017) Recombinant Antibodies to Arm Cytotoxic Lymphocytes in Cancer Immunotherapy. Transfusion Medicine and Hemotherapy 44:5, pages 337-350.
Crossref
Crossref
R. Ajina, D. AlDeghaither, S. Jablonski & L.M. Weiner. 2017. Comprehensive Medicinal Chemistry III. Comprehensive Medicinal Chemistry III
32
65
.
Fa Yang, Weihong Wen & Weijun Qin. (2016) Bispecific Antibodies as a Development Platform for New Concepts and Treatment Strategies. International Journal of Molecular Sciences 18:1, pages 48.
Crossref
Crossref
Jingjing Wu, Christina Liu, Stella T. Tsui & Delong Liu. (2016) Second-generation inhibitors of Bruton tyrosine kinase. Journal of Hematology & Oncology 9:1.
Crossref
Crossref
Jingjing Wu, John Savooji & Delong Liu. (2016) Second- and third-generation ALK inhibitors for non-small cell lung cancer. Journal of Hematology & Oncology 9:1.
Crossref
Crossref
Uwe Reusch, Kimberly H. Harrington, Chelsea J. Gudgeon, Ivica Fucek, Kristina Ellwanger, Michael Weichel, Stefan H.J. Knackmuss, Eugene A. Zhukovsky, Judith A. Fox, Lori A. Kunkel, Jeanmarie Guenot & Roland B. Walter. (2016) Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia. Clinical Cancer Research 22:23, pages 5829-5838.
Crossref
Crossref
Todd A. Fehniger & Megan A. Cooper. (2016) Harnessing NK Cell Memory for Cancer Immunotherapy. Trends in Immunology 37:12, pages 877-888.
Crossref
Crossref
Jonathan D. Kiefer & Dario Neri. (2016) Immunocytokines and bispecific antibodies: two complementary strategies for the selective activation of immune cells at the tumor site. Immunological Reviews 270:1, pages 178-192.
Crossref
Crossref
Maelig G. Morvan & Lewis L. Lanier. (2015) NK cells and cancer: you can teach innate cells new tricks. Nature Reviews Cancer 16:1, pages 7-19.
Crossref
Crossref
Shintaro Taki, Haruhiko Kamada, Masaki Inoue, Kazuya Nagano, Yohei Mukai, Kazuma Higashisaka, Yasuo Yoshioka, Yasuo Tsutsumi & Shin-ichi Tsunoda. (2015) A Novel Bispecific Antibody against Human CD3 and Ephrin Receptor A10 for Breast Cancer Therapy. PLOS ONE 10:12, pages e0144712.
Crossref
Crossref
Katherine Linder, Deepthi Gandhiraj, Madhura Hanmantgad, Karen Seiter & Delong Liu. (2016) Complete remission after single agent blinatumomab in a patient with pre-B acute lymphoid leukemia relapsed and refractory to three prior regimens: hyperCVAD, high dose cytarabine mitoxantrone and CLAG. Experimental Hematology & Oncology 5:1.
Crossref
Crossref
Shundong Cang, Chaitanya Iragavarapu, John Savooji, Yongping Song & Delong Liu. (2015) ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development. Journal of Hematology & Oncology 8:1.
Crossref
Crossref
Jingjing Wu, Jiaping Fu, Mingzhi Zhang & Delong Liu. (2015) Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia. Journal of Hematology & Oncology 8:1.
Crossref
Crossref
Jingjing Wu, Jiaping Fu, Mingzhi Zhang & Delong Liu. (2015) AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy. Journal of Hematology & Oncology 8:1.
Crossref
Crossref
Melissa M. Berrien-Elliott, Rizwan Romee & Todd A. Fehniger. (2015) Improving natural killer cell cancer immunotherapy. Current Opinion in Organ Transplantation 20:6, pages 671-680.
Crossref
Crossref
Tomohiro Osaki, Shingo Fujisawa, Masahiro Kitaguchi, Masaya Kitamura & Takeshi Nakanishi. (2015) Development of a bispecific antibody tetramerized through hetero-associating peptides. FEBS Journal 282:22, pages 4389-4401.
Crossref
Crossref
Tao Liu, Juanjuan Du, Xiaozhou Luo, Peter G Schultz & Feng Wang. (2015) Homogeneously modified immunoglobulin domains for therapeutic application. Current Opinion in Chemical Biology 28, pages 66-74.
Crossref
Crossref
Achim RotheStephanie Sasse, Max S. ToppDennis A. Eichenauer, Horst HummelKatrin S. ReinersMarkus Dietlein, Georg Kuhnert, Joerg KesslerCarolin Buerkle, Miroslav Ravic, Stefan Knackmuss, Jens-Peter Marschner, Elke Pogge von StrandmannPeter Borchmann & Andreas Engert. (2015) A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma. Blood 125:26, pages 4024-4031.
Crossref
Crossref
Natalia Nuñez-Prado, Marta Compte, Seandean Harwood, Ana Álvarez-Méndez, Simon Lykkemark, Laura Sanz & Luis Álvarez-Vallina. (2015) The coming of age of engineered multivalent antibodies. Drug Discovery Today 20:5, pages 588-594.
Crossref
Crossref
Cormac Sheridan. (2015) Amgen's bispecific antibody puffs across finish line. Nature Biotechnology 33:3, pages 219-221.
Crossref
Crossref
Barbara Geering & Martin Fussenegger. (2015) Synthetic immunology: modulating the human immune system. Trends in Biotechnology 33:2, pages 65-79.
Crossref
Crossref